US user fee date for Lundbeck's Serdolect passes without action
This article was originally published in Scrip
Executive Summary
The PDUFA date for Lundbeck's atypical antipsychotic Serdolect (sertindole), for the treatment of schizophrenia, has passed without action from the US FDA.